Selective serotonin reuptake inhibitors (SSRIs) represent the most common treatment for major depression. However, their efficacy is variable and incomplete. In order to elucidate the cause of such incomplete efficacy, we explored the hypothesis positing that SSRIs may not affect mood per se but, by enhancing neural plasticity, render the individual more susceptible to the influence of the environment. Consequently, SSRI administration in a favorable environment promotes a reduction of symptoms, whereas in a stressful environment leads to a worse prognosis. To test such hypothesis, we exposed C57BL/6 mice to chronic stress in order to induce a depression-like phenotype and, subsequently, to fluoxetine treatment (21 days), while being exposed to either an enriched or a stressful condition. We measured the most commonly investigated molecular, cellular and behavioral endophenotypes of depression and SSRI outcome, including depression-like behavior, neurogenesis, brain-derived neurotrophic factor levels, hypothalamic-pituitary-adrenal axis activity and long-term potentiation. Results showed that, in line with our hypothesis, the endophenotypes investigated were affected by the treatment according to the quality of the living environment. In particular, mice treated with fluoxetine in an enriched condition overall improved their depression-like phenotype compared with controls, whereas those treated in a stressful condition showed a distinct worsening. Our findings suggest that the effects of SSRI on the depression- like phenotype is not determined by the drug per se but is induced by the drug and driven by the environment. These findings may be helpful to explain variable effects of SSRI found in clinical practice and to device strategies aimed at enhancing their efficacy by means of controlling environmental conditions.Molecular Psychiatry advance online publication, 15 September 2015; doi:10.1038/mp.2015.142.

Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment / Alboni, S; van Dijk, R. M; Poggini, Silvia; Milior, Giampaolo; Perrotta, M; Drenth, T; Brunello, N; Wolfer, D. P; Limatola, Cristina; Amrein, I; Cirulli, F; Maggi, Laura; Branchi, Igor. - In: MOLECULAR PSYCHIATRY. - ISSN 1359-4184. - 22:4(2017), pp. 552-561. [10.1038/mp.2015.142]

Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment

POGGINI, SILVIA;MILIOR, GIAMPAOLO;Perrotta, M;LIMATOLA, Cristina;MAGGI, Laura;BRANCHI, Igor
2017

Abstract

Selective serotonin reuptake inhibitors (SSRIs) represent the most common treatment for major depression. However, their efficacy is variable and incomplete. In order to elucidate the cause of such incomplete efficacy, we explored the hypothesis positing that SSRIs may not affect mood per se but, by enhancing neural plasticity, render the individual more susceptible to the influence of the environment. Consequently, SSRI administration in a favorable environment promotes a reduction of symptoms, whereas in a stressful environment leads to a worse prognosis. To test such hypothesis, we exposed C57BL/6 mice to chronic stress in order to induce a depression-like phenotype and, subsequently, to fluoxetine treatment (21 days), while being exposed to either an enriched or a stressful condition. We measured the most commonly investigated molecular, cellular and behavioral endophenotypes of depression and SSRI outcome, including depression-like behavior, neurogenesis, brain-derived neurotrophic factor levels, hypothalamic-pituitary-adrenal axis activity and long-term potentiation. Results showed that, in line with our hypothesis, the endophenotypes investigated were affected by the treatment according to the quality of the living environment. In particular, mice treated with fluoxetine in an enriched condition overall improved their depression-like phenotype compared with controls, whereas those treated in a stressful condition showed a distinct worsening. Our findings suggest that the effects of SSRI on the depression- like phenotype is not determined by the drug per se but is induced by the drug and driven by the environment. These findings may be helpful to explain variable effects of SSRI found in clinical practice and to device strategies aimed at enhancing their efficacy by means of controlling environmental conditions.Molecular Psychiatry advance online publication, 15 September 2015; doi:10.1038/mp.2015.142.
2017
neuronal plasticity; depression; SSRI; environment
01 Pubblicazione su rivista::01a Articolo in rivista
Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment / Alboni, S; van Dijk, R. M; Poggini, Silvia; Milior, Giampaolo; Perrotta, M; Drenth, T; Brunello, N; Wolfer, D. P; Limatola, Cristina; Amrein, I; Cirulli, F; Maggi, Laura; Branchi, Igor. - In: MOLECULAR PSYCHIATRY. - ISSN 1359-4184. - 22:4(2017), pp. 552-561. [10.1038/mp.2015.142]
File allegati a questo prodotto
File Dimensione Formato  
Alboni_Fluoxetine-effects_2017.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 458.83 kB
Formato Adobe PDF
458.83 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/854981
Citazioni
  • ???jsp.display-item.citation.pmc??? 39
  • Scopus 133
  • ???jsp.display-item.citation.isi??? 106
social impact